脑心通治疗冠心病并心力衰竭患者血清C-反应蛋白变化临床意义.docVIP

脑心通治疗冠心病并心力衰竭患者血清C-反应蛋白变化临床意义【摘要】 目的 观察慢性心力衰竭（CHF）患者血清C-反应蛋白（CRP）的变化及脑心通的影响。方法 将CHF患者306例随机分为脑心通治疗组及对照组，两组均按CHF治疗指南给予常规治疗，治疗组另外服用脑心通，两组治疗前后检查总胆固醇（TC）、C-反应蛋白、左室射血分数（LVEF）。结果 8周后，治疗组TC、CRP与对照组比较均有不同程度降低，LVEF则有明显提高（P0．05）。结论 CRP可预测心血管疾病的危险，可作为预测心力衰竭患者预后的一个观察指标，脑心通可降低CRP水平，改善心力衰竭患者的预后。? 【关键词】慢性心力衰竭；C-反应蛋白；脑心通胶囊 ?? Naoxintong treatment of coronary artery disease in patients with heart failure 306 cases clinical significance of changes of C-Reactive protein YANG Xin-yuan,WAN Ping,MA Xin-yu.Heart Department,Zhumadian Center Hospital,Henan 463000,China ? 【Abstract】 Objective To observe the chronic heart failure patients with C-reactive protein (CRP) changes in the brain and heart-effects.Methods 306 cases of chronic heart failure patients were randomly divided into Naoxintong treatment and contrast groups, according to two groups of patients with chronic heart failure (CHF) treatment guidelines for routine treatment, the treatment group taking Naoxintong addition, inspect the two groups before and after treatment: total cholesterol (TC), C-reactive protein, left ventricular ejection fraction (LVEF).Results Eight weeks after the treatment group TC, CRP compared with the control group were reduced to varying degrees, LVEF was significantly improved (P0．05).Conclusion CRP can predict the risk of cardiovascular disease, as predicted the prognosis of patients with heart failure an observation indicators, Naoxintong can reduce CRP levels, improve the prognosis of patients with heart failure.【Key words】Chronic heart failure；C-reactive protein；Naoxintong capsules 慢性心力衰竭作为各种心血管疾患的终末期阶段，已成为目前的一种常见病、多发病，随着卫生保健水平的不断进步，我国心力衰竭的发生也在逐年增加，尤其是冠心病心力衰竭，增加更为显著。在重症心力衰竭患者中一年的死亡率可达50%，严重危害着人民的健康。笔者从2006年7月到2007年6月对冠心病心力衰竭患者在常规治疗的基础上加用脑心通治疗，结果发现脑心通治疗组较对照组患者C反应蛋白水平下降，生活质量改变，病死率下降。现报告如下。? 1 资料和方法? 1．1 一般资料 选择2006年7月到2007年6月住院的冠心病并慢性心力衰竭患者共306例，CHF的诊断符合Carlson-Boston标准，NYHA分级Ⅱ~Ⅳ级，病程6个月~9年（4．02±2．12）年，其中男182例，女124例，年龄54~81岁，平均（63±9．2）岁。随机分成脑心通组156例，对照组150例。两组患者在年龄、性别、心功能分级上差异